Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?

Protagonist Therapeutics (PTGX) announced a $300M share repurchase program, funded by cash reserves and collaboration payments. The program may be executed through open market purchases or other transactions, with timing and amounts dependent on market conditions and other factors. As of June 30, 2026, the company had $849.5M in cash, cash equivalents, and marketable securities, excluding recent milestone payments.

Protagonist Therapeutics (PTGX) reported a $162.8M profit in Q2 2026, reversing a $34.8M loss from the prior year. The turnaround was driven by milestone payments for two drugs, ICOTYDE and rusfertide, with cash reserves reaching $849.5M. ICOTYDE, approved for psoriasis, triggered a $50M payment and potential $580M more from J&J. Rusfertide, awaiting FDA decision, has already brought in $200M from Takeda, with more milestones pending.

FDA approval of MIMRYLO triggered $275M in payments to Protagonist Therapeutics (PTGX), including a $200M opt-out fee and a $75M milestone. PTGX chose royalties over a 50:50 profit split with Takeda (TAK), opting for non-dilutive capital and lower execution risk. PTGX is eligible for up to $875M in additional milestones. The royalty structure ranges from 14% to 29% on worldwide net sales.

FDA approved Protagonist Therapeutics' and Takeda's drug rusfertide (Mimrylo) for polycythemia vera. Mimrylo, a weekly injection, controls red blood cell overproduction. Takeda has not disclosed the price. Analysts forecast peak sales up to $2B. Protagonist's stock has nearly tripled in a year. Mimrylo is Takeda's second of three anticipated drug launches.

Protagonist Therapeutics (PTGX) shares fell 6.5% after FDA approval of MIMRYLO, a drug for polycythemia vera, triggered a $275M milestone payment from Takeda. The approval validates Protagonist's peptide platform and could reshape treatment approaches. However, the stock's high valuation and concentration risk remain concerns.

Protagonist Therapeutics (PTGX) announced FDA approval of MIMRYLO, a first-in-class treatment for polycythemia vera. The approval triggers $275M in milestone payments and potential royalties. Phase 3 trial results showed 76.9% of patients responded to the treatment. MIMRYLO is commercialized by Takeda under a 2024 agreement.